| Literature DB >> 32695426 |
Muhammad Eid Akkawi1, Mohamad Haniki Nik Mohamed1, Mohd Aznan Md Aris2.
Abstract
BACKGROUND: Potentially inappropriate prescribing (PIP) is associated with the incidence of adverse drug reactions, drug-related hospitalization and other negative outcomes in older adults. After hospitalization, older adults might be discharged with several types of PIPs. Studies have found that the lack of healthcare professionals' (HCPs) knowledge regarding PIP is one of the major contributing factors in this issue. The purpose of this study is to investigate the impact of a multifaceted intervention on physicians' and clinical pharmacists' behavior regarding potentially inappropriate medication (PIM) and potential prescribing omission (PPO) among hospitalized older adults.Entities:
Keywords: Academic detailing; Older adults; Potential prescribing omission; Potentially inappropriate medication; Smartphone app
Year: 2020 PMID: 32695426 PMCID: PMC7367269 DOI: 10.1186/s40545-020-00236-0
Source DB: PubMed Journal: J Pharm Policy Pract ISSN: 2052-3211
Specifying the target behavior
| Target behavior | Prescribing medications for hospitalized older adults |
|---|---|
| Physicians and hospital pharmacists. | |
Follow the criteria for prescribing in older adults. Check the appropriateness of each medication intended to be prescribed for an older adult. | |
| During writing prescriptions and reviewing medications of older adults. | |
| At the point of care. | |
| Every time they prescribe and review medications for older adults. | |
| Alone, or in collaboration with other colleagues. |
Fig. 1The behavior change wheel. Used with a permission from [28]
Fig. 2Screenshot shows searching for captopril-related recommendations on Plus65 Med©
Characteristics of the study population (N: 480)
| Variable | Control group ( | Intervention group ( |
|---|---|---|
| Age (year) | ||
| Mean (SD) | 71.9 (5.8) | 72.9 (5.7) |
| Median (IQR) | 70 (67–75) | 72 (68–81) |
| Sex | ||
| Male [ | 141 (58.8) | 108 (45) |
| Female [ | 99 (41.3) | 132 (55) |
| Race | ||
| Malay [ | 180 (75) | 171 (71.3) |
| Chinese [ | 46 (19.2) | 54 (22.5) |
| Indian [ | 14 (5.8) | 15 (6.2) |
| AC-CCI | ||
| Mean (SD) | 4.6 (1.6) | 4.83 (1.7) |
| Median (IQR) | 4 (3–5) | 4 (4–6) |
| Discharge medications | ||
| Mean (SD) | 5.9 (2.5) | 6.2 (2.5) |
| Median (IQR) | 6 (4–7) | 6 (5–8) |
| History of hospitalization (during the last 12 months) | ||
| Yes [ | 88 (36.7) | 76 (31.7) |
| No [ | 152 (63.3) | 164 (68.3) |
SD standard deviation, IQR interquartile range, AC-CCI age combined Charlson comorbidity index.
Fig. 3Distribution of PIMs among the two groups
Comparison of prevalence rates of PIM among the control and intervention groups
| Type of PIMs according to STOPP criteria | Control group | Intervention group |
|---|---|---|
| “Any duplicate drug class prescription” | 2 (0.8) | 0 |
| “Aspirin plus clopidogrel as secondary stroke prevention, unless the patient has a coronary stent(s) inserted in the previous 12 months or concurrent acute coronary syndrome or has a high grade symptomatic carotid arterial stenosis” | 3 (1.3) | 0 |
| “Aspirin in combination with vitamin K antagonist, direct thrombin inhibitor or factor Xa inhibitors in patients with chronic atrial fibrillation” | 1 (0.4) | 0 |
| “Ticlopidine in any circumstances” | 5 (2.1) | 7 (2.9) |
| “First-generation antihistamines” | 1 (0.4) | 1 (0.4) |
| “NSAID’s if eGFR < 50 ml/min/1.73m2” | 1 (0.4) | 1 (0.4) |
| “Metformin if eGFR < 30 ml/min/1.73m2” | 6 (2.5) | 4 (1.7) |
| “Drugs likely to cause constipation in patients with chronic constipation where non-constipating alternatives are available” | 1 (0.4) | 0 |
| “Proton pump inhibitor for uncomplicated peptic ulcer disease or erosive peptic oesophagitis at full therapeutic dosage for > 8 weeks” | 14 (5.8) | 13 (5.4) |
| “Anti-muscarinic bronchodilators with a history of narrow-angle glaucoma or bladder outflow” | 2 (0.8) | 0 |
| “Long-term NSAID or colchicine (> 3 months) for chronic treatment of gout where there is no contraindication to a xanthine-oxidase inhibitor” | 2 (0.8) | 1 (0.4) |
| “Sulphonylureas with a long duration of action with type 2 diabetes mellitus” | 1 (0.4) | 0 |
| “Beta-blockers in diabetes mellitus with frequent hypoglycaemic episodes” | 10 (4.2) | 4 (1.7) |
| “Vasodilator drugs with persistent postural hypotension” | 23 (9.6) | 24 (10%) |
| “Use of regular opioids without concomitant laxative” | 0 | 4 (1.7) |
Fig. 4Distribution of PPOs among the study group
Comparison of the prevalence rate of PPO among the control and intervention groups
| Type of PPOs according to START criteria | Control Group | Intervention group |
|---|---|---|
| “Vitamin K antagonists or direct thrombin inhibitors or factor Xa inhibitors in the presence of chronic atrial fibrillation” | 2 (0.8) | 7 (2.9) |
| “Antiplatelet therapy with a documented history of coronary, cerebral or peripheral vascular disease” | 10 (4.2) | 5 (2.1) |
| “Statin therapy with a documented history of coronary, cerebral or peripheral vascular disease” | 11 (4.6) | 11 (4.6) |
| “Angiotensin Converting Enzyme (ACE) inhibitor with systolic heart failure and/or documented coronary artery disease” | 30 (12.5)* | 16 (6.7)* |
| “Beta-blocker with ischaemic heart disease” | 22 (9.2) | 16 (6.7) |
| “Appropriate beta-blocker (bisoprolol, nebivolol, metoprolol or carvedilol) with stable systolic heart failure” | 6 (2.5) | 6 (2.5) |
| “Regular inhaled ß2 agonist or antimuscarinic bronchodilator mild to moderate asthma or COPD” | 11 (4.6) | 17 (7.1) |
| “Regular inhaled corticosteroid for moderate-severe asthma or COPD” | 10 (4.2) | 6 (2.5) |
| “Vitamin D supplements in older people who are housebound or experiencing falls or with osteopenia” | 37 (15.4)** | 14 (5.8)** |
| “Xanthine-oxidase inhibitors with a history of recurrent episodes of gout” | 2 (0.8) | 3 (1.3) |
| “ACE inhibitor or Angiotensin Receptor Blocker (if intolerant of ACE inhibitor) in diabetes with evidence of renal disease” | 20 (8.3) | 29 (12.1) |
| “Alpha-1 receptor blocker with symptomatic prostatism, where prostatectomy is not considered necessary” | 9 (3.8) | 6 (2.5) |
| “5-alpha-reductase inhibitor with symptomatic prostatism, where prostatectomy is not considered necessary” | 12 (5.0) | 9 (3.8) |
COPD chronic obstructive pulmonary disease.
*p = 0.03; **p = 0.001